Mattias F Lindberg

6PUBLICATIONS
11CO-AUTHORS
Characterisation of biological macromoleculesMolecular targetsBiologically active moleculesClinical pharmacology and therapeuticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 14, 2026
Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography.

|Feb 12, 2026
Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 iPSC-derived neural cells.

Nicole R West, Mattias F Lindberg, Julien Dairou

|Dec 05, 2023
Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate.

Mattias F Lindberg, Emmanuel Deau, Frédéric Miege

|Jul 24, 2023
Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.

Emmanuel Deau, Mattias F Lindberg, Frédéric Miege

|Mar 06, 2023
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.

Mattias F Lindberg, Emmanuel Deau, Jonas Arfwedson

|Jun 24, 2020
Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells.

Somsundar V Muralidharan, Lisa M Nilsson, Mattias F Lindberg

Pageof 1

Frequent Collaborators

5 joint publications

Laurent Meijer

2 joint publications

Stefan Knapp

2 joint publications

Julien Dairou

1 joint publications

Somsundar V Muralidharan